Nishimura K, Izumi T
Department of Pulmonary Medicine and Environmental Respiratory Diseases, Kyoto University.
Nihon Rinsho. 1996 Nov;54(11):3073-7.
In asthmaticus with relatively stable control, inhaled beta agonists are the primary drugs used to relieve symptoms which are mild and does not necessitate patients to visit emergency rooms. Global strategy for asthma management and prevention NHLBI/WHO workshop report gives inhaled beta agonists a specific position as a "reliever". Long-acting beta agonists such as salmeterol and formoterol were developed as a compensatory drug for "controllers". They have prolonged duration of bronchodilation effects with more than 12 hours. When asthmatic patients given high doses of inhaled corticosteroids do not enjoy best management, oral slow-releasing theophylline would be considered as one of next additional drugs of choice.
在病情控制相对稳定的哮喘持续状态患者中，吸入型β受体激动剂是用于缓解轻度症状且无需患者前往急诊室的主要药物。《全球哮喘防治创议：美国国立心、肺、血液研究所/世界卫生组织研讨会报告》赋予吸入型β受体激动剂“缓解药物”的特定地位。长效β受体激动剂如沙美特罗和福莫特罗作为“控制药物”的补充药物而研发。它们具有超过12小时的延长支气管舒张作用持续时间。当给予高剂量吸入性糖皮质激素的哮喘患者未获得最佳治疗效果时，口服缓释茶碱可被视为下一种备选药物之一。
